文献速递乳腺癌放疗

乳腺癌患者对超大分割放射治疗的采用情况

Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-12-24

该研究分析了本机构在支持超大分割全乳照射(ultra-HF-WBI)的高质量临床试验发表后,对导管原位癌(DCIS)和早期浸润性乳腺癌(ESBC)患者采用该方案的情况。2020年3月至2021年5月共665例患者,249例(37.4%)接受了超大分割全乳照射,使用率从2020年3-4月的4.3%升至2020年7-8月的45.5%(P < .001)。医生间使用率差异显著(0%至75.6%),医生因素解释21.7%的变异。

要点

  • 超大分割全乳照射使用率从2020年3-4月的4.3%升至2020年7-8月的45.5%(P < .001)。
  • 与使用增加相关的患者因素包括年龄≥50岁、低级别全乳照射未包括低位腋窝、无放疗boost和较远旅行距离(P < .03)。
  • 医生间超大分割全乳照射使用率从0%至75.6%,医生变异解释21.7%的结局方差。

核心结论

  • 支持超大分割全乳照射的随机证据发表后,本机构超大分割全乳照射的采用率大幅增加。
  • 超大分割全乳照射优先用于较低风险疾病患者,提示在长期数据成熟期间对该新方法进行了仔细选择。
  • 医生层面的显著差异可能反映对改变实践所需的证据标准缺乏共识。

研究设计与样本

  • 回顾性分析2020年3月至2021年5月在本院主院区和区域院区接受全乳照射的所有DCIS或ESBC患者的放射分割处方。
  • 从电子病历提取人口学和临床特征,从执照数据收集治疗医生特征。
  • 采用分层逻辑回归模型识别与超大分割全乳照射(26 Gy分5次每日照射[UK-FAST-FORWARD]或28.5 Gy分5次每周照射[UK-FAST])采用相关的因素。

主要发现

  • 共纳入665例患者,中位年龄61.5岁,478例(71.9%)为浸润性激素受体阳性乳腺癌。
  • 21名医生治疗了纳入患者,249例(37.4%)接受了超大分割全乳照射。
  • 超大分割全乳照射使用率从2020年3-4月的4.3%(2/46)升至2020年7-8月的高点45.5%(45/99)(P < .001)。
  • 与超大分割全乳照射使用增加相关的患者因素包括年龄≥50岁、低级别全乳照射未包括低位腋窝、无放疗boost和较远旅行距离(P < .03)。
  • 医生变异解释结局方差的21.7%,治疗医生超大分割全乳照射使用率范围为0%至75.6%,未发现测量的医生特征与超大分割全乳照射使用相关。

关键数值与推荐

  • 超大分割全乳照射方案为26 Gy分5次每日照射(UK-FAST-FORWARD)或28.5 Gy分5次每周照射(UK-FAST)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The first high-quality clinical trial to support ultrahypofractionated whole-breast irradiation (ultra-HF-WBI) for invasive early-stage breast cancer (ESBC) was published in April 2020, coinciding with the beginning of the COVID-19 pandemic. We analyzed adoption of ultra-HF-WBI for ductal carcinoma in situ (DCIS) and ESBC at our institution after primary trial publication. METHODS AND MATERIALS: We evaluated radiation fractionation prescriptions for all patients with DCIS or ESBC treated with WBI from March 2020 to May 2021 at our main campus and regional campuses. Demographic and clinical characteristics were extracted from the electronic medical record. Treating physician characteristics were collected from licensure data. Hierarchical logistic regression models identified factors correlated with adoption of ultra-HF-WBI (26 Gy in 5 daily factions [UK-FAST-FORWARD] or 28.5 Gy in 5 weekly fractions [UK-FAST]). RESULTS: Of 665 included patients, the median age was 61.5 years, and 478 patients (71.9%) had invasive, hormone-receptor-positive breast cancer. Twenty-one physicians treated the included patients. In total, 249 patients (37.4%) received ultra-HF-WBI, increasing from 4.3% (2 of 46) in March-April 2020 to a high of 45.5% (45 of 99) in July-August 2020 (P < .001). Patient factors associated with increased use of ultra-HF-WBI included older age (≥50 years old), low-grade WBI without inclusion of the low axilla, no radiation boost, and farther travel distance (P < .03). Physician variation accounted for 21.7% of variance in the outcome, with rate of use of ultra-HF-WBI by the treating physicians ranging from 0% to 75.6%. No measured physician characteristics were associated with use of ultra-HF-WBI. CONCLUSIONS: Adoption of ultra-HF-WBI at our institution increased substantially after the publication of randomized evidence supporting its use. Ultra-HF-WBI was preferentially used in patients with lower risk disease, suggesting careful selection for this new approach while long-term data are maturing. Substantial physician-level variation may reflect a lack of consensus on the evidentiary standards required to change practice.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Corrigan KL, Lei X, Ahmad N, et al. Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol. 2021. PMID: 35387420. doi:10.1016/j.adro.2021.100877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。